Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: A longitudinal analysis

The Lancet Infectious Diseases

Volumn 13, Issue 12, 2013, Pages 1021-1028

  Mugwanya, Kenneth K ^a,b   Donnell, Deborah ^a,c   Celum, Connie ^a   Thomas, Katherine K ^a   Ndase, Patrick ^a   Mugo, Nelly ^a,d,e   Katabira, Elly ^b   Ngure, Kenneth ^a,e,f   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF NAIROBI   (Kenya)

^e KENYATTA NATIONAL HOSPITAL   (Kenya)

^f JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; PLACEBO; TENOFOVIR;

ADULT; ARTICLE; CONDOM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEISSERIA GONORRHOEAE; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; TRACHOMA; TREATMENT DURATION; UNPROTECTED SEX;

ADULT; ANTI-RETROVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; RISK-TAKING; SEXUAL BEHAVIOR;

EID: 84887619507     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70226-3     Document Type: Article

References (27)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367:399-410.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012, 367:423-434.
4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381:2083-2090.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
7. Vissers DCJ, Voeten HACM, Nagelkerke NJD, Habbema JDF, de Vlas SJ The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 2008, 3:e2077.
8. Guest G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis 2008, 35:1002-1008.
9. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367:411-422.
10. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, USA; March 3-6, 2013. 26.
11. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One 2011, 6:e25828.
12. Carroll N. Application of segmented regression analysis to the Kaiser Permanente Colorado critical drug interaction program. Proceedings of the Fifthteenth Annual Western Users of SAS Software Conference; Universal City, California, USA; November 5-7, 2008.
13. Shardell M, Harris AD, El-Kamary SS, Furuno JP, Miller RR, Perencevich EN Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007, 45:901-907.
14. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002, 27:299-309.
15. Hu MC, Pavlicova M, Nunes EV Zero-inflated and hurdle models of count data with extra zeros: examples from an HIV-risk reduction intervention trial. Am J Drug Alcohol Abuse 2011, 37:367-375.
16. Cassell MM, Halperin DT, Shelton JD, Stanton D Risk compensation: the Achilles' heel of innovations in HIV prevention?. BMJ 2006, 332:605-607.
17. Eaton LA, Kalichman S Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007, 4:165-172.
18. Liu AY, Grant RM, Buchbinder SP Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 2006, 296:863-865.
19. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep 2010, 7:210-219.
20. Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2011, 55:8-13.
21. Kong X, Kigozi G, Nalugoda F, et al. Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am J Epidemiol 2012, 176:875-885.
22. Pinkerton SD Sexual risk compensation and HIV/STD transmission: empirical evidence and theoretical considerations. Risk Anal 2001, 21:727-736.
23. Abbas UL, Anderson RM, Mellors JW Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007, 2:e875.
24. Attia S, Egger M, Muller M, Zwahlen M, Low N Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009, 23:1397-1404.
25. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375:2092-2098.
26. Ndase P, Celum C, Thomas K, et al. Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships. J Acquir Immune Defic Syndr 2012, 59:65-71.
27. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis 2004, 38:1586-1591.